Selectivity and Kinetic Requirements of HDAC Inhibitors as Progranulin Enhancers for Treating Frontotemporal Dementia
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Summary Frontotemporal dementia (FTD) arises from neurodegeneration in the frontal, insular, and anterior temporal lobes. Autosomal dominant causes of FTD include heterozygous mutations in the GRN gene causing haploinsufficiency of progranulin (PGRN) protein. Recently, histone deacetylase (HDAC) inhibitors have been identified as enhancers of PGRN expression, although the mechanisms through which GRN is epigenetically regulated remain poorly understood. Using a chemogenomic toolkit, including optoepigenetic probes, we show that inhibition of Class I HDACs is sufficient to upregulate PGRN in human neurons and only inhibitors with apparent fast binding to their target HDAC complexes are capable of enhancing PGRN expression. Moreover, we identify regions in the GRN promoter in which elevated H3K27 acetylation and transcription factor EB (TFEB) occupancy correlate with HDAC-inhibitor mediated upregulation of PGRN. These findings have implications for epigenetic and cis-regulatory mechanisms controlling human GRN expression and may advance translational efforts to develop targeted therapeutics for treating PGRN-deficient FTD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Characterization of the CLEAR network reveals an integrated control of cellular clearance pathways
Palmieri, M., Impey, S., Kang, H., di Ronza, A., Pelz, C., Sardiello, M., & Ballabio, A. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr306 · Cited by 1,022 · cited 1×
“In addition, TFEB has been linked to the expression of members of the computationally derived CLEAR (Coordinated Lysosomal Expression and Regulation) network, and is thought to bind to either a full CLEAR sequence (50-TCACGTGA-30) or a partial CLEAR motif (50-TCACG-30) (Palmieri et al., 2011).”
Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A
Butler, K. V., Kalin, J., Brochier, C., Vistoli, G., Langley, B., & Kozikowski, A. P. (2010) · Journal of the American Chemical Society · doi:10.1021/ja102758v · Cited by 801 · cited 1×
“To this end, we first tested the class IIb HDAC6-selective inhibitors, ACY-1215 (ricolinostat) and tubastatin A, and a class I HDAC8-selective inhibitor, PCI-34051, in human NPCs and neurons at a range of concentrations previously reported in the literature to be effective (Iaconelli et al., 2015; Butler et al., 2010;…”
Lui, H., Zhang, J., Makinson, S. R., Cahill, M. K., Kelley, K. W., Huang, H.-Y., Shang, Y., Oldham, M. C., Martens, L. H., Gao, F., et al. (2016) · Cell · doi:10.1016/j.cell.2016.04.001 · Cited by 729 · cited 1×
“Because many patients with PGRN-deficient FTD exhibit accumulation of TDP-43within neurons (van Swieten and Heutink, 2008) and Grn / mice are known to exhibit lysosomal defects (Lui et al., 2016), future studies can be directed toward understanding whether HDAC inhibitors can help to alleviate these phenotypes in cult…”
Chemical phylogenetics of histone deacetylases
Bradner, J. E., West, N., Grachan, M. L., Greenberg, E. F., Haggarty, S. J., Warnow, T., & Mazitschek, R. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.313 · Cited by 720 · cited 1×
“However, since SAHA is a relatively non-selective HDAC inhibitor targeting class I (HDAC1/2/3,8), IIb (HDAC6/10), and IV (HDAC11) HDAC isoforms, the precise molecular mechanisms behind PGRN regulation in human neurons have yet to be elucidated (Bradner et al., 2010; Bantscheff et al., 2011).”
Self-citationDetermination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors
Khan, N., Jeffers, M., Kumar, S., Hackett, C., Boldog, F., Khramtsov, N., Qian, X., Mills, E., Berghs, S. C., Carey, N., et al. (2008) · Biochemical Journal · doi:10.1042/bj20070779 · Cited by 713
Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes
Bantscheff, M., Hopf, C., Savitski, M. M., Dittmann, A., Grandi, P., Michon, A.-M., Schlegl, J., Abraham, Y., Becher, I., Bergamini, G., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1759 · Cited by 659
Balasubramanian, S., Ramos, J., Luo, W., Sirisawad, M., Verner, E., & Buggy, J. J. (2008) · Leukemia · doi:10.1038/leu.2008.9 · Cited by 458
Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia
Herman, D., Jenssen, K., Burnett, R., Soragni, E., Perlman, S. L., & Gottesfeld, J. M. (2006) · Nature Chemical Biology · doi:10.1038/nchembio815 · Cited by 442 · cited 1×
“This slow-on/slow-off mechanism has been shown to be essential for induction of the FXN gene, with the hypothesis that residence time on the HDAC is key for this induction (Herman et al., 2006; Chou et al., 2008).”
Lauffer, B. E. L., Mintzer, R., Fong, R., Mukund, S., Tam, C., Zilberleyb, I., Flicke, B., Ritscher, A., Fedorowicz, G., Vallero, R., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.490706 · Cited by 429 · cited 1×
“Besides varying in their isoform selectivity from the hydroxamates, CI-994 and Cpd-60 also differ in terms of their binding kinetics (Bantscheff et al., 2011; Lauffer et al., 2013; Wagner et al., 2016; Chou et al., 2008).”
Pimelic Diphenylamide 106 Is a Slow, Tight-binding Inhibitor of Class I Histone Deacetylases
Chou, C. J., Herman, D., & Gottesfeld, J. M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m807045200 · Cited by 223 · cited 4×
“Whereas hydroxamates have a fast-on/ fast-off mechanism of action, CI-994 and Cpd-60 have a slowon/slow-off mechanism of action (Schroeder et al., 2013; Chou et al., 2008).”
InfluentialTargeting Class I Histone Deacetylases in a “Complex” Environment
Millard, C. J., Watson, P. J., Fairall, L., & Schwabe, J. W. R. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.12.006 · Cited by 180 · cited 1×
“In support of the latter, it is well known that HDACs are part of large, macromolecular complexes that may include other HDAC family members (Bantscheff et al., 2011; Millard et al., 2017).”
Schroeder, F. A., Lewis, M. C., Fass, D. M., Wagner, F. F., Zhang, Y.-L., Hennig, K. M., Gale, J., Zhao, W.-N., Reis, S., Barker, D. D., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071323 · Cited by 146 · cited 1×
“Whereas hydroxamates have a fast-on/ fast-off mechanism of action, CI-994 and Cpd-60 have a slowon/slow-off mechanism of action (Schroeder et al., 2013; Chou et al., 2008).”
Self-citation
Cited by
An update on genetic frontotemporal dementia
Greaves, C. V., & Rohrer, J. D. (2019) · Journal of Neurology · doi:10.1007/s00415-019-09363-4 · Cited by 500
Xia, C., Tao, Y., Li, M., Che, T., & Qu, J. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.9073 · Cited by 136
“Tubastatin A, an inhibitor of HDAC6, increases the acetylation level of TFEB accordingly (113).”
Li, Y., Sang, S., Ren, W., Pei, Y., Bian, Y., Chen, Y., & Sun, H. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113874 · Cited by 77
Butler, V. J., Gao, F., Corrales, C. I., Cortopassi, W. A., Caballero, B., Vohra, M., Ashrafi, K., Cuervo, A. M., Jacobson, M. P., Coppola, G., et al. (2019) · PLOS Genetics · doi:10.1371/journal.pgen.1008295 · Cited by 39
Kitir, B., Maolanon, A. R., Ohm, R. G., Colaço, A. R., Fristrup, P., Madsen, A. S., & Olsen, C. A. (2017) · Biochemistry · doi:10.1021/acs.biochem.7b00725 · Cited by 38
Metadata
- Authors
- She, A., Kurtser, I., Reis, S. A., Hennig, K., Lai, J., Lang, A., Zhao, W.-N., Mazitschek, R., Dickerson, B. C., Herz, J., & Haggarty, S. J.
- Venue
- Cell Chemical Biology
- Publisher
- Elsevier BV
- Published
- 2017-07
- Volume
- 24
- Issue
- 7
- Pages
- 892-906.e5
- ISSN
- 2451-9448 (ISSN-L)
- 2451-9456
- OpenAlex
- W2734750982
- Cited by
- 50
- References
- 12
- FWCI
- 1.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.